文献速递细菌感染、耐药与抗菌药物

社区获得性肺炎住院治疗中加用大环内酯类抗生素

Addition of Macrolide Antibiotics for Hospital Treatment of Community-Acquired Pneumonia.
PubMed 文献 · J Infect Dis · 2025-01-01

该研究分析英国牛津郡2016至2024年8872例住院社区获得性肺炎成人患者电子健康数据,初始治疗为阿莫西林或阿莫西林-克拉维酸,采用逆概率治疗加权评估加用大环内酯类对30天全因死亡、出院时间和SOFA评分变化的影响;结果显示加用大环内酯类与30天死亡率、出院时间及SOFA评分下降均无证据相关,结论认为在人群水平加用大环内酯类未改善临床结局,其潜在获益需与不良反应和抗菌药物耐药风险权衡。

要点

  • 加用大环内酯类与30天死亡率无证据相关,阿莫西林联合组边际OR 1.05(95%CI 0.75-1.47)。
  • 阿莫西林-克拉维酸联合组30天死亡边际OR 1.12(95%CI 0.93-1.34),无证据相关。
  • 加用大环内酯类与出院时间及SOFA评分下降无证据相关,各严重程度亚组结果一致。

核心结论

  • 在人群水平,加用大环内酯类与社区获得性肺炎患者临床结局改善无关联。
  • 加用大环内酯类的潜在获益应与不良反应和抗菌药物耐药风险权衡。

研究设计与样本

  • 分析英国牛津郡2016至2024年8872例住院社区获得性肺炎成人患者的电子健康数据。
  • 患者初始治疗为阿莫西林或阿莫西林-克拉维酸,采用逆概率治疗加权评估加用大环内酯类的效应。

主要发现

  • 加用大环内酯类与30天死亡率无证据相关:阿莫西林联合组边际OR 1.05(95%CI 0.75-1.47),阿莫西林-克拉维酸联合组边际OR 1.12(95%CI 0.93-1.34)。
  • 加用大环内酯类与出院时间无证据差异:阿莫西林组限制性平均损失天数+1.76天(-1.66至+5.19),阿莫西林-克拉维酸组+0.44天(-1.63至+2.51)。
  • 加用大环内酯类与SOFA评分下降无关联。
  • 结果在各严重程度亚组及缺失协变量插补的敏感性分析中一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Guidelines recommend combining macrolides with β-lactam antibiotics for moderate-to-high severity community-acquired pneumonia (CAP); however, macrolides pose risks of adverse events and anti-microbial resistance. METHODS: We analyzed electronic health data from 8872 adults hospitalized with CAP in Oxfordshire, UK (2016-2024), initially treated with amoxicillin or co-amoxiclav. Using inverse probability treatment weighting, we examined the effects of adjunctive macrolides on 30-day all-cause mortality, time to hospital discharge, and changes in Sequential Organ Failure Assessment (SOFA) score. RESULTS: There was no evidence of an association between adjunctive macrolides and 30-day mortality (marginal odds ratio 1.05 [95% CI 0.75-1.47] for amoxicillin with vs. without macrolide; 1.12 [0.93-1.34] for co-amoxiclav with vs. without macrolide); and no evidence of a difference in time to discharge (restricted mean days lost +1.76 days [-1.66, +5.19] for amoxicillin, +0.44 days [-1.63, +2.51] for co-amoxiclav). Macrolide use was not associated with SOFA score decreases. Results were consistent across severity sub-groups and sensitivity analyses with missing covariates imputed. CONCLUSIONS: At a population level, the addition of macrolides was not associated with improved clinical outcomes for patients with CAP. The potential benefits of additional macrolides should be weighed against the risks of adverse effects and anti-microbial resistance.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Wei J, Walker AS, Eyre DW, et al. Addition of Macrolide Antibiotics for Hospital Treatment of Community-Acquired Pneumonia. J Infect Dis. 2025. PMID: 39718980. doi:10.1093/infdis/jiae639

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。